A J Schrader

Summary

Country: Germany

Publications

  1. ncbi request reprint Application of retinoids in the treatment of renal cell carcinoma--a futile effort?
    Andres J Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    Anticancer Drugs 15:819-24. 2004
  2. pmc Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011
    Andres Jan Schrader
    Department of Urology, Ulm University Medical Center, Prittwitzstrasse 43, 89075 Ulm, Germany
    ISRN Urol 2012:748235. 2012
  3. ncbi request reprint Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
    Andres Jan Schrader
    Department of Urology, Ulm University Medical Center, Ulm, Germany Electronic address
    Eur Urol 65:30-6. 2014
  4. pmc High CRP values predict poor survival in patients with penile cancer
    Sandra Steffens
    Department of Urology, Hannover Medical School, Hannover, Germany
    BMC Cancer 13:223. 2013
  5. pmc Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
    Barbara Stein
    Department of Urology, Hannover Medical School, Carl Neuberg Str, 1, Hannover, D 30625, Germany
    BMC Cancer 13:101. 2013
  6. pmc Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients
    Sandra Steffens
    Department of Urology, Hannover Medical School, Carl Neuberg Str, 1, D 30625, Hannover, Germany
    BMC Cancer 12:399. 2012
  7. doi request reprint Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
    Andres J Schrader
    Department of Urology, Ulm University Medical Center, Ulm, Germany
    Int J Urol 19:903-7. 2012
  8. pmc Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells
    Friedemann Zengerling
    Department of Urology, Ulm University, Ulm 89075, Germany E Mails A J S M S M V C Department of Physiology, Charite Universitatsmedizin, Campus Benjamin Franklin, Berlin 14195, Germany E Mails B N M H
    Int J Mol Sci 13:11530-42. 2012
  9. pmc JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells
    Martin Laschak
    Department of Urology, Ulm University, Prittwitzstrasse 43, 89075, Ulm, Germany
    BMC Cancer 12:130. 2012
  10. pmc Caveolin 1 protein expression in renal cell carcinoma predicts survival
    Sandra Steffens
    Department of Urology, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, 30625, Germany
    BMC Urol 11:25. 2011

Collaborators

Detail Information

Publications55

  1. ncbi request reprint Application of retinoids in the treatment of renal cell carcinoma--a futile effort?
    Andres J Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    Anticancer Drugs 15:819-24. 2004
    ..This Commentary summarizes preclinical and clinical trials investigating efficacy and toxicity of retinoids in the treatment of RCC...
  2. pmc Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011
    Andres Jan Schrader
    Department of Urology, Ulm University Medical Center, Prittwitzstrasse 43, 89075 Ulm, Germany
    ISRN Urol 2012:748235. 2012
    ..This review was composed to give an overview on the flood of novel findings dealing with diagnostics and therapy of both localized and advanced RCC. The most clinically relevant data are discussed in detail...
  3. ncbi request reprint Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
    Andres Jan Schrader
    Department of Urology, Ulm University Medical Center, Ulm, Germany Electronic address
    Eur Urol 65:30-6. 2014
    ..Enzalutamide is a second-generation nonsteroidal antiandrogen that has recently been approved for the same indication...
  4. pmc High CRP values predict poor survival in patients with penile cancer
    Sandra Steffens
    Department of Urology, Hannover Medical School, Hannover, Germany
    BMC Cancer 13:223. 2013
    ..The aim of this study was to evaluate the prognostic significance of the preoperative serum CRP level in patients with squamous cell carcinoma (SCC) of the penis...
  5. pmc Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
    Barbara Stein
    Department of Urology, Hannover Medical School, Carl Neuberg Str, 1, Hannover, D 30625, Germany
    BMC Cancer 13:101. 2013
    ..To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC)...
  6. pmc Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients
    Sandra Steffens
    Department of Urology, Hannover Medical School, Carl Neuberg Str, 1, D 30625, Hannover, Germany
    BMC Cancer 12:399. 2012
    ..To evaluate the prognostic significance of the pre-operative C-reactive protein (CRP) serum level in patients with renal cell cancer (RCC)...
  7. doi request reprint Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
    Andres J Schrader
    Department of Urology, Ulm University Medical Center, Ulm, Germany
    Int J Urol 19:903-7. 2012
    ..Thus, even today in the era of targeted agents, a neoadjuvant approach should only be made in patients with localized or locally advanced renal cell carcinoma, which primarily seem to be absolutely inaccessible by (partial) nephrectomy...
  8. pmc Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells
    Friedemann Zengerling
    Department of Urology, Ulm University, Ulm 89075, Germany E Mails A J S M S M V C Department of Physiology, Charite Universitatsmedizin, Campus Benjamin Franklin, Berlin 14195, Germany E Mails B N M H
    Int J Mol Sci 13:11530-42. 2012
    ..The present findings warrant further investigations on sorafenib as an option for the treatment of advanced AR-positive PCa...
  9. pmc JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells
    Martin Laschak
    Department of Urology, Ulm University, Prittwitzstrasse 43, 89075, Ulm, Germany
    BMC Cancer 12:130. 2012
    ..In consequence NO-donors could be of special interest for the treatment of deregulated androgen receptor(AR)-signaling in castration resistant prostate cancer (CRPC)...
  10. pmc Caveolin 1 protein expression in renal cell carcinoma predicts survival
    Sandra Steffens
    Department of Urology, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, 30625, Germany
    BMC Urol 11:25. 2011
    ..The aim of this study was to elucidate the caveolin-1 (CAV1) protein expression in renal cell cancer (RCC) and to determine its potential prognostic relevance...
  11. pmc Signatures of human regulatory T cells: an encounter with old friends and new players
    Susanne Pfoertner
    Department of Mucosal Immunity, German Research Centre for Biotechnology, Braunschweig, Germany
    Genome Biol 7:R54. 2006
    ..Thus far, genomic studies on TReg cells were restricted to murine systems, and requirements for their development, maintenance, and mode of action in humans are poorly defined...
  12. pmc Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer
    Sandra Waalkes
    Department of Urology, Hannover Medical School, Germany
    BMC Cancer 10:503. 2010
    ..The aim of this study was to elucidate the role of FN1 in development of renal cell cancer (RCC) and to determine a prognostic relevance for optimal clinical management...
  13. doi request reprint Metastatic non-clear cell renal cell carcinoma: current therapeutic options
    Andres J Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    BJU Int 101:1343-5. 2008
    ..The medium-term aim should be to tailor the most advantageous therapy for each patient with respect to his/her individual RCC subtype and physical condition...
  14. ncbi request reprint Metastatic renal cell carcinoma: recent advances and current therapeutic options
    Andres Jan Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse, 35043 Marburg, Germany
    Anticancer Drugs 19:235-45. 2008
    ..In the following, we give a concise overview on results of current trials in metastatic renal cell carcinoma published within 2007. Moreover, we will translate these results into therapeutic options and recommendations...
  15. doi request reprint [Gender-specific characteristics and survival of renal cell carcinoma]
    A J Schrader
    Klinik für Urologie und Kinderurologie, Philipps Universitat Marburg, Marburg, Deutschland
    Urologe A 47:1182, 1184-6. 2008
    ..Renal cell carcinoma (RCC) occurs twice as often in men as in women; however, the influence of gender on stage, grade, subtype and prognosis has not been studied in detail...
  16. doi request reprint Incidence and long-term prognosis of papillary renal cell carcinoma
    A J Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse 1, Marburg 35043, Germany
    J Cancer Res Clin Oncol 135:799-805. 2009
    ..In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC)...
  17. doi request reprint Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma
    Andres Jan Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse, 35043 Marburg, Germany
    J Cancer Res Clin Oncol 135:1693-9. 2009
    ..However, data on the prognostic impact of overweight in RCC is still conflicting. We assessed whether different body mass index (BMI) levels at the time of surgery had an effect on the long-term prognosis of RCC patients...
  18. doi request reprint Urinary collecting system invasion in renal cell carcinoma: incidence and long-term prognosis
    Andres Jan Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    Int J Urol 16:718-22. 2009
    ..The aim of the present study was to assess incidence and long-term prognosis of RCC patients with and without UCS involvement...
  19. ncbi request reprint Clinical impact of MDR1-expression in testicular germ cell cancer
    A J Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse, D 35043 Marburg, Germany
    Exp Oncol 29:212-6. 2007
    ..The aim of this study was to investigate the prognostic value of MDR1 expression in primary tumor tissue to predict necrosis or viable cancer in residual tumor masses after systemic chemotherapy for advanced testicular germ cell cancer...
  20. ncbi request reprint [Application monitoring of the use of sorafenib in papillary renal cell carcinoma]
    A J Schrader
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH, Baldingerstrasse, 35033 Marburg
    Urologe A 46:1291. 2007
  21. ncbi request reprint Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells
    A J Schrader
    Department of Cell Biology, Immunology and Experimental Oncology, National Research Centre for Biotechnology GBF, Braunschweig, Germany
    Melanoma Res 10:355-62. 2000
    ..In conclusion, the use of this multiple-marker microcontamination assay allowed for molecular and prognostic classification of advanced malignant melanoma...
  22. ncbi request reprint Tumour microdissemination and survival in metastatic melanoma
    A J Schrader
    Department of Cell Biology, Immunology and Experimental Oncology, National Research Centre for Biotechnology GBF, D 38 124 Braunschweig, Germany
    Anticancer Res 20:3619-24. 2000
    ..001). In addition, the multiple marker RT-PCR analysis was more reliable and sensitive than a single molecular marker assay for the detection of melanoma cells...
  23. pmc Giant hydronephrosis mimicking progressive malignancy
    Andres Jan Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse, D 35043 Marburg, Germany
    BMC Urol 3:4. 2003
    ..Cases of giant hydronephroses are rare and usually contain no more than 1-2 litres of fluid in the collecting system. We report a remarkable case of giant hydronephrosis mimicking a progressive malignant abdominal tumour...
  24. ncbi request reprint Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma
    Andres J Schrader
    Department of Urology, Philipps University Medical School, 35043 Marburg, Germany
    Anticancer Drugs 16:581-5. 2005
    ..However, toxicity and costs are considerable, and clinical benefit is uncertain. Therefore, thalidomide/IL-2 might not represent a promising therapeutic approach for this subgroup of patients...
  25. ncbi request reprint Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches
    A J Schrader
    Department of Urology, Philipps University Medical School, Baldingerstrasse, 35043 Marburg, Germany
    J Cancer Res Clin Oncol 132:137-49. 2006
    ..Until today, there is no standard therapeutic procedure for the growing number of patients who relapse following first-line therapy and desire further active treatment...
  26. ncbi request reprint Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer
    Andres J Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    BJU Int 97:461-5. 2006
  27. ncbi request reprint [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]
    A J Schrader
    Klinik für Urologie und Kinderurologie Marburg, Universitätsklinikum Giessen und Marburg
    Aktuelle Urol 37:429-35; quiz 423-4. 2006
    ....
  28. ncbi request reprint Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
    A J Schrader
    Department of Cell Biology, Immunology and Experimental Oncology, National Research Centre for Biotechnology GBF, Braunschweig, Germany
    Anticancer Drugs 11:143-8. 2000
    ..This article summarizes recent trials using either chemotherapy alone or chemotherapy plus the administration of IFN-alpha and/or IL-2 to evaluate the benefit of a combined biochemotherapy...
  29. pmc Partial nephrectomy using porcine small intestinal submucosa
    Thomas J Schnoeller
    Department of Urology, Ulm University Medical Center, Prittwitzstrasse 43, D 89075 Ulm, Germany
    World J Surg Oncol 9:126. 2011
    ..We prospectively evaluated the pros and cons of using porcine small intestinal submucosa (SIS, Surgisis®) to close the renal defect after nephron-sparing surgery...
  30. ncbi request reprint [The use of Surgisis® optimizes and simplifies partial nephrectomy for large renal tumors]
    T J Schnoeller
    Klink für Urologie, Universitatsklinikum Ulm, Prittwitzstraße 43, Ulm, Germany
    Urologe A 52:246-51. 2013
    ..The main complications of nephron-sparing surgery, particularly for large and centrally located tumors, are postoperative parenchymal bleeding and urinary fistulas after opening the urinary collecting system (UCS)...
  31. doi request reprint [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]
    P J Olbert
    Klinik für Urologie und Kinderurologie, Philipps Universitat Marburg, Baldingerstrasse, Marburg
    Aktuelle Urol 40:164-8. 2009
    ..In the absence of other effective and approved drugs we evaluated the toxicity and efficacy of intermittent-docetaxel-chemotherapy in patients whose cancers progressed after successful first-line docetaxel therapy...
  32. doi request reprint [Radical cystectomy and ileal neobladder reconstruction in elderly female patients over 70 years old: morbidity, functional and oncological long-term results]
    F Jentzmik
    Klinik für Urologie, Universitätsklinik Ulm, Prittwitzstraße 43, 89075 Ulm, Deutschland
    Urologe A 51:1419-23. 2012
    ..The aim of this study was to assess long-term clinical, functional and oncological outcome in elderly women (≥70 years) who were treated by radical cystectomy and ileal neobladder reconstruction for invasive bladder cancer...
  33. doi request reprint [Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression]
    P J Olbert
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg, Marburg an der Lahn, Deutschland
    Urologe A 47:1133-4, 1136. 2008
    ..They are accompanied by an objective clinical response, as we were able to show recently. Immunostimulatory DNA holds promise to be a novel therapeutic agent in TCC...
  34. doi request reprint [Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker]
    A Hegele
    Klinik für Urologie und Kinderurologie, Universitätsklinika Giessen und Marburg, Standort Marburg, Marburg an der Lahn, Deutschland
    Urologe A 47:1137-40. 2008
    ..Upcoming investigations are necessary to prove the value of the potential marker cFN during follow-up and its impact as a prognostic factor for recurrence and progression of TCC...
  35. doi request reprint [Value of positron emission tomography in urological neoplasms: more form than substance?]
    J Muller
    Klinik für Urologie, Universitatsklinikum Ulm, Prittwitzstraße 43, 89075 Ulm, Deutschland
    Urologe A 51:331-40. 2012
    ..Differences in using PET/CT for primary diagnosis, staging, or restaging are outlined separately. Appropriate indications for the use in clinical practice are cited...
  36. ncbi request reprint Management of muscle-invasive bladder cancer
    J Mueller
    Department of Urology University Hospital Ulm, Ulm, Germany
    Minerva Urol Nefrol 65:235-48. 2013
    ..This review summarizes current data and aims to help guiding through several available recommendations on therapy and management of MIBC. ..
  37. doi request reprint [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis]
    C Frohme
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg, Standort Marburg, Baldingerstrasse, 35043, Marburg, Deutschland
    Urologe A 49:639-44. 2010
    ..The aim of this prospective study was to evaluate the efficacy of singular and repeated botulinum-A toxin (BTX-A) injections in the bladder detrusor muscle in patients suffering nonneurogenetic OAB...
  38. doi request reprint [Clinical stage I seminoma. Is surveillance a new therapy standard?]
    F Zengerling
    Klinik für Urologie und Kinderurologie, Universitatsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm, Deutschland
    Urologe A 52:1265-9. 2013
    ..While surveillance, adjuvant radiotherapy and adjuvant chemotherapy were seen as equal therapeutic alternatives up to a few years ago, recently published studies make it necessary to adopt a more differentiated approach...
  39. doi request reprint [Pelvic lymphadenitis after total hip arthroplasty : Mimicking of lymph node metastases in a patient with prostate cancer]
    S Sevinc
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg, Baldingerstrasse, 35043, Marburg, Deutschland
    Urologe A 49:952-6. 2010
    ....
  40. doi request reprint [Renal masses in pregnancy. Diagnostics and therapeutic management]
    T J Schnöller
    Klinik für Urologie, Universitätsklinik Ulm, Prittwitzstraße 43, 89075, Ulm, Deutschland
    Urologe A 50:1064-7. 2011
    ..The aim of this article is to summarize the clinical experience in treating pregnant women with renal cancer against the background of those cases published in the literature...
  41. doi request reprint [Update uro-oncology: scientific meetings 2011]
    A Hegele
    Klinik für Urologie und Kinderurologie, Philipps Universitat Marburg, Germany
    Aktuelle Urol 43:13-27. 2012
    ..Furthermore the authors summarize and comment scientific approaches and the most interesting research on the different fields of urological malignancies...
  42. ncbi request reprint [Focus on tumor immunology of transitional cell carcinoma]
    P J Olbert
    Klinik für Urologie und Kinderurologie, Philipps Universitat Marburg
    Urologe A 46:1135-7. 2007
  43. doi request reprint [Fast-track concepts in the perioperative management of patients undergoing radical cystectomy and urinary diversion: review of the literature and research results]
    P J Olbert
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg, Baldingerstrasse, 35033, Marburg, Deutschland
    Urologe A 48:137-42. 2009
    ..Controlled clinical trials are needed to further evaluate important aspects of a standardized perioperative plan of care (including antibiotic regimen and earlier removal of ureteral and neobladder catheters)...
  44. doi request reprint [Intrathoracic hernia after laparoscopic nephrectomy: clinical manifestation and conservative management]
    C Frohme
    Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH Standort Marburg, Baldingerstrasse, 35043, Marburg, Deutschland
    Urologe A 48:1499-502. 2009
    ..In cases of lasting abdominal discomfort or pulmonary symptoms after abdominal surgery, radiological investigation to exclude intrathoracic hernia should be considered...
  45. doi request reprint [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value]
    J Muller
    Klinik für Urologie, Universitatsklinikum Ulm, Pritzwitzstraße 43, 89075 Ulm, Deutschland
    Urologe A 50:322-7. 2011
    ..Meta-analysis evaluating the accuracy and sensitivity of FDG (2-[(18)F]-fluoro-2-deoxy-D-glucose) positron emission tomography (PET) to predict viable residual tumours in patients with metastatic seminoma...
  46. ncbi request reprint Basic science and research in renal cell carcinoma: from workbench to bedside
    Axel Heidenreich
    Department of Urology and Pediatric Urology, Philipps University, Baldingerstrasse, 35043 Marburg, Germany
    Curr Opin Urol 13:457-62. 2003
    ....
  47. ncbi request reprint Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma
    Sandra Waalkes
    Department of Urology, Hannover Medical School, Carl Neuberg Str 1, 30625, Hannover, Germany
    World J Urol 28:283-8. 2010
    ..To assess the specific impact of urinary collecting system (UCS) invasion on the long-term prognosis of patients with renal cell carcinoma (RCC)...
  48. doi request reprint Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis
    Rolf von Knobloch
    Department of Urology, Franziskus Hospital, Bielefeld, Germany
    Urology 73:333-6. 2009
    ..To present data from all patients with adrenal involvement after prolonged follow-up and to revise our advice given in 1999. In 1999, we published our results for a large series of patients with adrenal metastasis from renal cell carcinoma...
  49. doi request reprint Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review
    Edwin Herrmann
    Department of Urology, University of Munster, Munster, Germany
    J Urol 183:460-6. 2010
    ..We examined papillary renal cell carcinoma prognostic variables and validated the 2002 UICC TNM staging system in a multicenter analysis...
  50. ncbi request reprint Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma
    Susanne Pfoertner
    Department of Cell Biology and Immunology, German Research Center for Biotechnology, Braunschweig, Germany
    Tumour Biol 26:313-23. 2005
    ..The genetic changes reported here contribute to a better understanding of the role of RA in RCC. They also provide new insights into CRABP-I-mediated signaling and gene expression...
  51. ncbi request reprint Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma
    Ulrike Goelden
    Department of Cell Biology and Immunology, German Research Centre for Biotechnology, Braunschweig, Germany
    Urol Int 75:269-76. 2005
    ..As the exact mechanisms of RA action and especially the role of the cellular retinoic acid-binding proteins (CRABP) still remain unclear, we studied the expression of CRABP-II and its potential influence on RA response in RCC...
  52. ncbi request reprint Impact of evidence-based interdisciplinary guidelines on testis cancer management
    Andres Jan Schrader
    Department of Urology, Philipps University Medical School, Marburg, Germany
    Cancer 106:313-9. 2006
    ..Therefore, patient collectives treated before the introduction of guidelines (Group A, 1990-1999, n = 234) and those thereafter (Group B, 2000-2002, n = 84) were compared for recurrence and survival...
  53. ncbi request reprint Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA-9: results of a prospective trial
    Carsten Henning Ohlmann
    Division of Oncological Urology, Department of Urology, University of Cologne, Cologne, Germany
    Urol Oncol 24:287-93. 2006
    ..Furthermore, we evaluated the clinical course of the patients being operated on with either method in terms of complications, postoperative recovery, and hospital stay...
  54. ncbi request reprint Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer
    Axel Hegele
    Department of Urology, Medical School, Philipps University Marburg, Germany
    BJU Int 99:330-4. 2007
    ....
  55. doi request reprint Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers
    Diana Julie Leeming
    Nordic Bioscience Diagnosis A S, Herlev Hovedgade 207, DK 2730 Herlev, Denmark
    Cancer Epidemiol Biomarkers Prev 17:1269-76. 2008
    ..Results suggest that alphaalphaCTX is superior to PSA and tALP for identifying patients having a high risk of metastatic disease and for monitoring skeletal progression in +BM prostate cancer patients during treatment...